Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded at DZ Bank

DZ Bank upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a strong sell rating to a hold rating in a research note published on Thursday,Zacks.com reports.

A number of other equities analysts have also recently issued reports on the stock. Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. Finally, Zacks Research cut shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 24th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Performance

Shares of Bayer Aktiengesellschaft stock opened at $11.75 on Thursday. The company has a market capitalization of $46.18 billion, a PE ratio of -10.59 and a beta of 0.70. The stock’s fifty day simple moving average is $12.03 and its 200 day simple moving average is $10.46. Bayer Aktiengesellschaft has a 12 month low of $5.70 and a 12 month high of $14.85. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Wednesday, March 4th. The company reported $0.18 EPS for the quarter, hitting analysts’ consensus estimates of $0.18. The company had revenue of $13.24 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.35%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. On average, research analysts predict that Bayer Aktiengesellschaft will post 1.31 EPS for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.